Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family in EU and MENA Regions
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced its strategic partnership with 3comma Medical GmbH, a commercial services firm that specializes in bringing innovative medical device products to international markets. Under this collaboration, 3comma will serve as the exclusive international (OUS) distributor in EU and MENA regions for Cagent Vascular, leveraging its extensive network, industry expertise, and market insights to expedite the adoption of the Serranator® PTA Serration Balloon Product Family. This expansion builds upon the company's commercial success and growth in the US market. The Serranator is a groundbreaking therapy for the treatment of peripheral artery disease (PAD) and chronic limb threatening ischemia (CLTI).
'We are excited to join forces with 3comma to accelerate adoption in international markets,' said Paul Wilson, Chief Commercial Officer of Cagent Vascular. 'Partnering with 3comma marks an exciting step forward in expanding global access to the Serranator portfolio and delivering cutting-edge solutions to patients around the world. 3comma's deep commercial experience with peripheral vascular products and quality service will strengthen our commercial efforts to ensure we maximize growth opportunities and rapidly scale our presence to match international demand.' Mr. Wilson added, 'We're especially excited to make Serranator more accessible to physicians, providing them with a better tool to enhance patient care and drive improved outcomes. '
Marc Paris, CEO and Managing Partner of 3comma, expressed enthusiasm about the partnership: 'We are thrilled to partner with Cagent Vascular and bring Serranator to physicians worldwide. Cagent's commitment to delivering high-quality products for the treatment of PAD and CLTI will be a valuable addition to the institutions we serve. By combining our comprehensive distribution capabilities with Cagent's innovative offerings, we aim to optimize PAD and CLTI treatment across the globe.'
Advancing Vascular Care with Innovative Serration Technology
Cagent Vascular remains committed to advancing vascular care by delivering high-quality, clinically effective solutions that improve patient outcomes. The company's proprietary serration balloon technology is designed to optimize vessel preparation, enhance arterial expansion, and address challenging lesion morphologies in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI).
The Serranator ® and Serranator SL-PRO™ PTA Serration Balloon Catheters are FDA-cleared, novel balloons using stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies with minimal recoil. By bringing a differentiated approach to vessel preparation, Cagent Vascular continues to support physicians in delivering optimal outcomes for patients with PAD and CLTI.
SOURCE: Cagent Vascular
Copyright Business Wire 2025.
PUB: 04/03/2025 09:41 AM/DISC: 04/03/2025 09:41 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
36 minutes ago
- Business Wire
Wolters Kluwer Updates Sentri7, Enhancing Pharmacy and Nursing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health today announced extensive updates to its Sentri7 ® Drug Diversion and Sentri7 ® Pharmacy solutions, reinforcing its commitment to innovation in medication safety, compliance, and patient care. These improvements further equip clinical teams with actionable, data-driven insights to streamline workflows for drug diversion and medication management, ultimately supporting better patient care. 'Our mission is to help healthcare organizations deliver safer, higher-quality care with solutions that optimize the workflows supporting patient care and compliance in today's demanding healthcare environment,' said Karen Kobelski, Vice President and General Manager of Clinical Surveillance Compliance & Data Solutions at Wolters Kluwer Health. " With our team's deep expertise in pharmacy, technology, and artificial intelligence, we're providing customers with critical insights and support to address challenges like medication management, drug diversion prevention, and the opioid crisis.' Sentri7 Drug Diversion delivers improved workflows The redesigned Sentri7 Drug Diversion solution introduces a more intuitive interface, enabling teams to detect and manage drug diversion threats with greater precision and efficiency. Healthcare organizations can now act faster and more effectively to mitigate risks, with features like: User-friendly dashboard: Consolidates essential risk factors and actionable insights into a single, user-friendly interface to streamline diversion detection follow-up. Refined HEAT™ scoring and trend analysis: Quickly identifies high-risk staff across multiple facilities with a Watch List that improves alert monitoring of priority areas of concern. Missing medication analysis: Saves time for busy nursing teams by reconciling medication transactions across care areas, enabling timely interventions. 'Sentri7 Drug Diversion has a very mature user interface. It is very straightforward. It is easy to use and train our diversion staff to use. The graphics are very clear to understand. The solution has a HEAT score that it gives when it suspects an employee of diversion. It promotes that information to us and tells us where there is suspicious activity rather than us having to look at the numbers and determine that on our own,' according to a pharmacy manager interviewed by KLAS Research, February 2025. Sentri7 Pharmacy updates support patient-centered care The updated Sentri7 Pharmacy solution delivers an efficient, patient-centric workflow to optimize medication therapies, safety and overall cost savings. Key updates include: User-friendly interface: Tailored to support rounding workflows for individual patients, in addition to managing targeted medication surveillance across the entire patient population. Enhanced documentation tools: Simplified and standardized data entry enhances reporting, enabling pharmacy teams to demonstrate impact with evidence-based metrics. Actionable Performance Insights: Provides clear key performance indicators on cost savings, departmental contributions, and patient outcomes. When asked about Wolters Kluwer's surveillance solution, one pharmacy analyst noted in a KLAS Research April 2025 interview, 'Wolters Kluwer is super engaging and allows for a lot of collaborative work with organizations. The vendor does a good job of meeting organizations where they are at and working toward solutions. Wolters Kluwer has just been great at engaging with end users on how to improve their Sentri7 Pharmacy Surveillance product. I would definitely recommend Sentri7 Pharmacy Surveillance.' Learn more about the enhanced Sentri7 solutions. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Yahoo
an hour ago
- Yahoo
Pet Supplies Plus and Wag N' Wash Report Double Digit Mid-Year Growth Amid Record Industry Highs
Pet Retail Brands Capitalize on Momentum as Pet and Franchise Industries Surge in 2025 CEO Chris Rowland Appointed to the Board of Franchise Group, Inc. to Support Continuous Success The Franchise Brands Further Position as Industry Leaders with Strong Growth and Positive Cash Flow LIVONIA, Mich., June 9, 2025 /PRNewswire/ -- With the franchise industry expected to generate $936.4 billion in economic output this year, pet retail franchise leaders Pet Supplies Plus and Wag N' Wash are capitalizing on the record-setting momentum with double-digit growth through the first half of 2025. The two brands have secured 15 new franchise agreements so far and are on track to open more than 25 stores in 2025, with a goal of selling 35 locations by year's end. The success of Pet Supplies Plus continues to earn national recognition. So far this year, the brand was ranked the #1 Pet Franchise in Entrepreneur's Franchise 500® for the 11th consecutive year, claimed the top spot in the publication's "Best of the Best" list, and secured #9 on its "Top Brands for Multi-Unit Owners" ranking. Additionally, Pet Supplies Plus was named to Forbes' prestigious "Best Customer Service" list for the second year in a row, outranking competitors and reinforcing its commitment to exceptional service. "The first half of 2025 has been incredibly successful and speaks to the strength of both Pet Supplies Plus and Wag N' Wash," said Nick Russo, Chief Development Officer of Pet Supplies Plus and Wag N' Wash. "Our rapid franchise growth and national recognition as top brands – not just in pet retail, but across franchising – demonstrate the power of our systems and our core mission of making pet services affordable and accessible. As interest in pet retail franchising continues to grow, both brands are well-positioned for an even stronger second half of the year." The pet industry is thriving alongside franchising in 2025. Over 94 million U.S. households now own at least one pet, up from 82 million in 2023. Despite ongoing economic uncertainty and high inflation, 77% of U.S. pet owners say the economy has not affected their pet ownership, emphasizing a continued commitment to keeping pets healthy, safe, and comfortable. As consumer spending in the pet category rises year over year, both Pet Supplies Plus and Wag N' Wash present strong opportunities for growth-minded franchisees. In a notable development that underscores Pet Supplies Plus and Wag N' Wash's influence within the larger retail space, Pet Supplies Plus CEO Chris Rowland was recently appointed to the board of Fusion Parent, LLC which is the successor parent to Franchise Group, Inc. His leadership and perspective will help shape the strategic direction of the organization and support their long-term growth. "Our team continues to build on a legacy of trust and consistency that resonates with both franchisees and pet parents," shared Rowland. "Looking ahead, we are more energized than ever. Our focus remains on strategic expansion, strong franchisee support, and maintaining the neighbor-first experience that truly sets us apart in a competitive market." Both Pet Supplies Plus and Wag N' Wash are actively seeking single and multi-unit owners to join their growing families. To learn more about the Pet Supplies Plus franchise opportunity, visit To learn more about the Wag N' Wash franchise opportunity, visit About Pet Supplies PlusPet Supplies Plus, a subsidiary of Franchise Group, Inc., is focused on making it easier to get better products and services for your pet. With over 725 locations and counting, the stores have a streamlined design making it easy to navigate a wide assortment of natural pet foods, goods, and services. Additionally, provides neighbors with additional shopping options to better meet their pet-shopping needs. Headquartered in Livonia, Michigan, Pet Supplies Plus ranked No. 20 in Entrepreneur's Annual Franchise 500® list and No. 33 on Forbes' list of 'Best Customer Service' brands in 2025. For more information on Pet Supplies Plus franchise opportunities, visit About Wag N' WashWag N' Wash Natural Pet Food & Grooming, a full-line dog grooming and self-wash specialty retail destination, has a mission to recognize, promote and foster the positive impact that companion pets and their humans have on each other. Wag N' Wash provides full-service grooming, self-wash facilities, baked dog treats, natural food, supplements, and toys. Wag N' Wash has ranked on Denver Business Journal's Colorado-Based Franchisors List, Franchise Times' Top 200+ List and Franchise Gator's Top 100 Franchisees List. Today, there are 27 Wag N' Wash locations open across the nation. To learn more about Wag N' Wash, please visit Media Contact: Ethan Gutstein, Fishman Public Relations, egutstein@ or 847.945.1300 View original content to download multimedia: SOURCE Pet Supplies Plus and Wag N' Wash Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
The Hackett Group ®: Digital World Class ® Finance Teams Operate at 45% Lower Cost and Deliver Faster, Smarter Insights
MIAMI--(BUSINESS WIRE)-- The Hackett Group, Inc. (NASDAQ: HCKT), a leading generative artificial intelligence (Gen AI) consultancy and executive advisory firm, today released its 2025 Digital World Class ® Finance research. The study highlights how top-performing finance organizations are redefining effectiveness and efficiency through Gen AI, automation, and digital modernization. Digital World Class® finance organizations operate at 45% lower cost as a percentage of revenue, deliver 74% faster executive insights and provide 57% faster forecasts. The Hackett Group ® defines Digital World Class ® finance organizations as those that achieve top-quartile performance in both business value and operational excellence. These organizations operate at 45% lower cost as a percentage of revenue, deliver 74% faster executive insights and provide 57% faster forecasts. They spend less time on data collection and more time generating analysis and insights – using Gen AI and analytics to support faster, smarter business decisions. 'As disruption accelerates, Gen AI gives finance leaders a once-in-a-generation opportunity to reimagine work and deliver breakthrough enterprise value,' said Martijn Geerling, managing director and Global practice leader at The Hackett Group ®. 'Digital World Class ® finance organizations are already leading the way.' Accelerating insight and value through Gen AI The 2025 research draws from global benchmarks and outlines five key performance areas where Digital World Class ® finance organizations outperform peers: 1. Business effectiveness Spend 68% more time on forward-looking analysis and strategic insights. Are 54% more likely to align business planning with annual budgeting. Have 48% lower days sales outstanding and 83% lower average days delinquent. 2. Digital enablement Approximately 2X more likely to enable cost center managers to enter budgets online and provide self-serve ad hoc reports. Nearly 100% enable customer account access online – 6X more than peers. Suppliers are 7X more likely to use self-service portals. 3. Customer and stakeholder experience Approximately 42% more stakeholders view finance as a valued business partner. About 25% more likely to generate billing electronically, with 48% fewer billing errors – as a result, receiving nearly 100% of receivables within terms. 4. Operational efficiency Have 35%-57% shorter close cycles than peers. Spend 57% less on planning and forecasting, while investing more in business analysis. Require up to 42% fewer full-time equivalents across key finance functions. 5. Business process automation Are 56% more likely to automate customer-to-cash processes, including billing and cash application. Approximately 80% of accounts payable workflows are fully automated. About 99% of journal entries are automated (vs. 85% for peers). Rethinking the finance operating model for the Gen AI era The path to Digital World Class ® performance will require reshaping the finance operating model. To close the gap, The Hackett Group ® outlines six levers for building a Gen AI-enabled finance function: Service design: Redesign core processes to support agentic workflows and customer-centric experiences. Technology: Rationalize outdated systems, embrace cloud-first tools, and apply Gen AI to accelerate reporting, forecasting, and analytics. Human capital: Upskill teams for AI collaboration, cultivate a culture of innovation, and develop leadership and business partnership skills. Analytics and information management: Champion enterprisewide data governance and ensure the finance data foundation is AI-ready. Service partnering: Outsource transactional tasks while focusing internal talent on strategic impact; collaborate with ethical AI partners. Organization and governance: Flatten hierarchies, build AI centers of excellence and adopt cross-functional, end-to-end service models. 'Digital World Class ® finance organizations are becoming trusted strategic partners by using Gen AI to automate routine work and elevate analysis,' said Vince Griffin, principal and Finance Executive Advisory practice leader at The Hackett Group ®. 'They are reshaping forecasting, planning and decision-making in ways that drive measurable business impact.' A public version of the research paper, ' Reimagine Finance Performance With Gen AI ', is available for free with registration. About The Hackett Group ® The Hackett Group, Inc. (NASDAQ: HCKT) is an IP and platform-based, Gen AI strategic consulting and executive advisory firm that enables Digital World Class ® performance. Using AI XPLR™ and ZBrain™ – our ideation through implementation platforms – our experienced professionals help organizations realize the power of Gen AI and achieve quantifiable, breakthrough results, allowing us to be key architects of their Gen AI journey. Our expertise is grounded in unparalleled best practices insights from benchmarking the world's leading businesses – including 97% of the Dow Jones Industrials, 90% of the Fortune 100, 70% of the DAX 40 and 51% of the FTSE 100. Visit us at Trademarks The Hackett Group ®, quadrant logo, and Digital World Class ® are the registered marks of The Hackett Group ®. Cautionary Statement Regarding 'Forward-Looking' Statements This release contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements including without limitation, words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' or other similar phrases or variations of such words or similar expressions indicating, present or future anticipated or expected occurrences or outcomes are intended to identify such forward-looking statements. Forward-looking statements are not statements of historical fact and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that may impact such forward-looking statements include without limitation, the ability of The Hackett Group ® to effectively market its digital transformation, our ability to transition our capabilities to support generative artificial intelligence (AI)-related consulting services and solutions and other consulting services, our ability to effectively integrate acquisitions, including the Spend Matters acquisition into our operations, our ability to manage joint ventures and successfully cooperate with our joint venture partners, competition from other consulting and technology companies that may have or develop in the future, similar offerings, the commercial viability of The Hackett Group ® and its services as well as other risk detailed in The Hackett Group's reports filed with the United States Securities and Exchange Commission. The Hackett Group ® does not undertake any duty to update this release or any forward-looking statements contained herein.
